Search
Now showing items 1-4 of 4
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
(NATURE PUBLISHING GROUP, 2020-01-21)
BACKGROUND: Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing the potential of repurposing this drug are underway. ...
Landscape of transcriptomic interactions between breast cancer and its microenvironment.
(NATURE PUBLISHING GROUP, 2019-07-15)
Solid tumours comprise mixtures of tumour cells (TCs) and tumour-adjacent cells (TACs), and the intricate interconnections between these diverse populations shape the tumour's microenvironment. Despite this complexity, ...
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
(NATL ACAD SCIENCES, 2019-06-18)
Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α-positive (ERα+) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism and regulating amino acid (AA) uptake. Here, ...
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.
(CELL PRESS, 2018-11-06)
Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study ...